IGEV +/- Bortezomib (VelcadeTM) as induction before high dose consolidation in relapsed/ refractory Hodgkin's lymphoma after first line treatment : a randomized phase II trial
Phase of Trial: Phase II
Latest Information Update: 24 Apr 2014
At a glance
- Drugs Bortezomib (Primary) ; Gemcitabine; Ifosfamide; Vinorelbine
- Indications Hodgkin's disease
- Focus Therapeutic Use
- 01 Sep 2010 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 01 Sep 2010 Actual end date (February 2010) added as reported by ClinicalTrials.gov.
- 01 Sep 2010 Planned end date changed from 1 Feb 2015 to 1 Feb 2010 as reported by ClinicalTrials.gov.